Aerie: Alcon Completes Acquisition of Aerie Pharmaceuticals
Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals (Aerie). Through the transaction, Alcon has added the commercial products Rocklatan and Rhopressa, as well as AR-15512, a Phase 3 product candidate for dry eye disease.
Read full article »
Aerie is a North Carolina-based pharmaceutical company that develops and commercializes novel therapies to treat open-angle glaucoma, ocular surface, and retinal diseases.
Read more